what is thymosin beta 4: Frequently asked questions

Select the 17-amino-acid TB-4 fragment for localized wound models (dermal punch biopsies, corneal abrasions, surgical incisions). It matches full-length Thymosin Beta 4 for epithelial migration rates, angiogenesis, and collagen deposition while offering better cost-efficiency and more predictable subcutaneous bioavailability. Reserve full-length Thymosin Beta 4 for systemic inflammation models, sepsis studies, or cardiac ischemia-reperfusion protocols where NF-κB inhibition and broad immunomodulation are primary endpoints. If budget allows, run a small pilot comparing both forms at equimolar doses across your specific model. Pathway activation can vary by tissue type and injury context.

Discard it immediately. Cloudiness indicates aggregation, precipitation, or contamination. All of which render the peptide unsuitable for experimental use. Aggregated peptides exhibit altered pharmacokinetics and can trigger immune responses in vivo that confound experimental endpoints. Common causes include reconstituting with water that was too cold, using non-sterile diluent, or exceeding the 28-day refrigerated shelf life. Prepare a fresh vial using room-temperature bacteriostatic water and sterile technique. If cloudiness recurs, the lyophilized powder itself may have degraded due to improper storage before reconstitution.

N-terminal acetylation is essential for biological activity. Non-acetylated Thymosin Beta-4 shows dramatically reduced half-life in serum and lower efficacy in cell migration assays. Contact the supplier immediately to confirm whether the product is N-acetylated. If documentation is unavailable, mass spectrometry can differentiate: acetylated TB-4 has molecular weight 4,963 Da, while non-acetylated would be 4,921 Da (42 Da difference from the acetyl group). Many research-grade suppliers acetylate by default because non-acetylated TB-4 has limited research utility, but verification prevents wasted experimental runs using an inactive peptide variant.

Verify that the TB-500 product contains the full 43-amino-acid acetylated sequence at ≥95% purity. If sequence and purity match published specifications for the original protocol, substitution is scientifically valid. TB-500 and TB-4 are nomenclature variants for the same peptide. Document the product source, lot number, and CoA in your methods section to ensure reproducibility. If the original protocol used a specific supplier's TB-4 and results cannot be replicated with a different supplier's TB-500, the discrepancy likely stems from purity differences, presence of aggregates, or incorrect storage conditions rather than fundamental molecular differences between correctly synthesized peptides.

Request certificate of analysis documentation for both products showing amino acid sequence, molecular weight via mass spectrometry, and HPLC purity. If both show 43-amino-acid sequence with N-terminal acetylation and molecular weight 4,963 Da, they are chemically identical. The separate listings reflect marketing differentiation or different manufacturing batches, not molecular differences. Some suppliers maintain separate SKUs for peptides synthesized at different scales or purity grades (e.g., 95% vs 98% purity), which represents legitimate product differentiation. If the supplier cannot provide mass spec data confirming sequence identity, the products may contain truncated sequences, non-acetylated variants, or contaminants that compromise experimental validity.

Extract dosing information, administration route, and species from each study's methods section. These variables influence outcomes far more than nomenclature. If both studies used peptides at equivalent purity (≥95%) with confirmed acetylation, differences in results stem from experimental design (injury model, timing of administration, endpoint measurement) rather than peptide differences. Meta-analyses combining 'Thymosin Beta-4' and 'TB-4' studies treat them as the same intervention when molecular specifications match. The nomenclature split creates indexing challenges in literature searches but doesn't represent distinct pharmacological entities.

Prepare single-use aliquots immediately after reconstituting the full vial. Divide the solution into sterile microcentrifuge tubes or glass vials, freeze at −20°C, and thaw only the volume needed for each experimental session. Limit freeze-thaw cycles to two maximum. Each cycle fragments a small percentage of peptide chains and reduces biological activity by approximately 10–15%. Label each aliquot with the reconstitution date and peptide concentration to prevent dosing errors. This approach extends usable life to 90–120 days while maintaining >95% potency, assuming no temperature excursions during storage.

Use equimolar dosing rather than equal mass dosing. The molecular weight difference (4,921 Da vs 1,815 Da for the 17-amino-acid fragment) means 5 mg of full-length Thymosin Beta 4 contains fewer moles of peptide than 5 mg of TB-4 fragment. Calculate molar equivalents before preparing stock solutions, and verify both peptides via mass spectrometry before beginning dose-response comparisons. Most apparent potency differences between forms result from incorrect dose normalization rather than genuine biological divergence.

Thymosin Alpha-1 and TB-500 (Thymosin Beta-4) are structurally unrelated peptides with entirely different mechanisms of action. Thymosin Alpha-1 is a 28-amino-acid immune-modulating peptide that enhances T-cell maturation and cytokine production, primarily used in immunology and infectious disease research. TB-500 is a 43-amino-acid actin-binding peptide focused on tissue repair, cell migration, and angiogenesis. The similar 'Thymosin' nomenclature reflects their historical co-isolation from thymus tissue but does not indicate functional similarity. If your research involves immune modulation, Thymosin Alpha 1 Peptide is the appropriate compound; if focused on wound healing or tissue regeneration, TB-500 is the correct selection.

Precipitation indicates the peptide has aggregated due to incorrect pH, ionic strength, or storage temperature. Do not attempt to redissolve by heating—elevated temperatures denature the peptide irreversibly. The most common cause is reconstitution with plain sterile water instead of bacteriostatic water or buffered saline. TB-500's isoelectric point at pH 4.5 means the peptide carries minimal net charge in unbuffered water, promoting aggregation. Discard the precipitated solution and reconstitute a fresh vial using bacteriostatic water (0.9% benzyl alcohol) or phosphate-buffered saline at pH 7.4, which provides ionic stabilization and prevents aggregation.

Reconstitute only the amount you'll use within 28 days. Once mixed with bacteriostatic water, both peptides remain stable at 2–8°C for approximately four weeks, after which aggregation and loss of bioactivity become measurable. For studies longer than four weeks, divide your peptide supply into multiple vials and reconstitute each batch as needed rather than reconstituting the full study supply upfront. Never freeze reconstituted peptide. Freeze-thaw cycles cause irreversible aggregation. If you're running a 12-week study, plan to reconstitute fresh peptide at weeks 1, 5, and 9.

Verify the amino acid length and molecular weight on the certificate of analysis. If the product contains the full 43-amino-acid sequence with molecular weight 4963.4 Da and N-terminal acetylation confirmed by mass spectrometry, it is functionally identical to TB-500 regardless of the label. Some suppliers use 'Thymosin Beta-4' to denote the naturally occurring peptide name, while others use 'TB-500' as the synthetic trade designation—both refer to the same molecule. If the CoA shows a molecular weight below 4900 Da or lists fewer than 43 amino acids, the product is a truncated fragment and will not deliver the expected bioactivity.

Lyophilized TB-500 can tolerate brief temperature excursions (up to 25°C for 48–72 hours) without significant degradation, provided the vial remains sealed and protected from moisture. Extended exposure above 4°C for more than one week begins to degrade the peptide, particularly the N-terminal acetylation, which is vulnerable to hydrolysis at elevated temperatures. If the freezer was above 0°C for fewer than 48 hours, the peptide likely retains full activity. If the excursion lasted longer or reached ambient temperature for more than 72 hours, consider requesting HPLC re-analysis or replacing the vial. Temperature logging is critical for maintaining chain of custody in GLP-compliant research—document any excursion and assess whether it falls within acceptable limits for your protocol.

This happens more often than it should. Some vendors market TB-500 as 'Thymosin Beta 4' because researchers use the terms interchangeably, but that substitution creates reproducibility problems. Request a certificate of analysis (COA) showing the molecular weight and amino acid sequence. If the molecular weight is below 1,000 Daltons, you received the fragment, not the full protein. Real Peptides provides full sequence verification and HPLC purity testing on every batch of TB 500 Thymosin Beta 4 to prevent exactly this kind of substitution error. If your vendor can't provide a COA within 24 hours of request, find a different supplier.

Switch to full Thymosin Beta 4 immediately. TB-500's actin-binding affinity is insufficient to replicate the cytoskeletal effects required for cell migration assays, wound contraction models, or any protocol where actin polymerization dynamics are a primary outcome measure. Using TB-500 in these contexts will produce inconclusive or negative results that don't reflect the compound's true activity. They reflect using the wrong tool. Verify your peptide source provides third-party HPLC and mass spectrometry data confirming you received the 43-amino-acid sequence, not the fragment.